Current Report Filing (8-k)
August 07 2017 - 7:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2017
Horizon Pharma Public Limited Company
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Ireland
|
|
001-35238
|
|
Not Applicable
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
Connaught House, 1
st
Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland
(Address of principal executive offices)
Registrants telephone number, including area code:
011-353-1-772-2100
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2
of the Securities Exchange Act of 1934.
Emerging
growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
|
Results of Operations and Financial Condition.
|
On August 7, 2017, Horizon Pharma
plc issued a press release announcing its financial results for the second quarter ended June 30, 2017. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press Release of Horizon Pharma plc, dated August 7, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: August 7, 2017
|
|
|
|
HORIZON PHARMA PUBLIC LIMITED COMPANY
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Paul W. Hoelscher
|
|
|
|
|
|
|
Paul W. Hoelscher
|
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer
|
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From May 2023 to May 2024